How the world’s biggest medical device maker made $2.5bn in sales from Ebola outbreaks
The Ebola virus pandemic has seen a new wave of sales for the world, as the global medical device industry is starting to recover from the crisis.
A new report from the International Federation of Robotics (IFR) says global sales of medical devices, including vaccines, medicines and implants, increased 6.7 per cent last year, up from 6.1 per cent the year before.
It says that the global market is projected to reach $9.2 billion by 2019, which is up from $946 million in 2014.
The report says that these sales are mostly driven by medical devices sold in developing countries.
It also points to the rise of the healthcare industry, which has been able to generate substantial income from its sale of medical products.
In some countries, it has been more successful than other industries in making money.
In many countries, the medical industry is experiencing a shortage of medical supplies, so they are now increasingly using their own money to purchase goods, according to the report.
The report also notes that many countries are using their purchasing power to purchase medical devices from other countries, which can be used to build up a surplus.
In 2016, there were 8.3 million medical devices in use in the world.
By 2019, there will be more than 14 million, according the report, and that number is projected at 15 million by 2022.
According to the IFR report, the global health crisis has also hit the manufacturing sector, with manufacturing revenues from Ebola vaccines and vaccines for use in developing and developing countries declining by an average of 14 per cent.
The International Federation for Robotics said that it expects the global supply chain to remain stable during the Ebola pandemic, as many medical devices can be purchased by manufacturers in a single shipment and they can continue to provide healthcare to patients.
The IFR also notes the impact that the Ebola crisis has had on the pharmaceutical sector.
The association noted that there is an increase in the use of antibiotics and vaccines, as well as the increased availability of pharmaceuticals in developing nations.
It also said that the pharmaceutical industry is not immune to the pandemic.
For instance, in countries like Brazil, the price of antibiotics used in developing regions of the world has risen significantly, as has the amount of drugs used to treat Ebola patients.